Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice

Journal of Korean Diabetes ◽

10.4093/jkd.2017.18.3.135 ◽

2017 ◽

Vol 18 (3) ◽

pp. 135

Author(s):

Nam Hoon Kim ◽

Sin Gon Kim

Keyword(s):

Clinical Practice ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Safety Issues ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors

Download Full-text

B-PO05-144 COMPARING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON NEW-ONSET ATRIAL FIBRILLATION AND ISCHEMIC STROKE

Heart Rhythm ◽

10.1016/j.hrthm.2021.06.1063 ◽

2021 ◽

Vol 18 (8) ◽

pp. S430-S431

Author(s):

Sharen Lee ◽

Jiandong Zhou ◽

Xiansong Wang ◽

Carlin Chang ◽

Tong Liu ◽

...

Keyword(s):

Atrial Fibrillation ◽

Ischemic Stroke ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Onset Atrial Fibrillation ◽

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/review4 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Decision letter for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v2/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease

Journal of Diabetes Investigation ◽

10.1111/jdi.13147 ◽

2019 ◽

Vol 11 (1) ◽

pp. 22-24

Author(s):

Shin‐ichi Araki

Keyword(s):

Kidney Disease ◽

Diabetic Kidney Disease ◽

Dipeptidyl Peptidase ◽

Combined Effect ◽

Diabetic Kidney ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors

Download Full-text

Indirect Comparison to Evaluate the Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors (DPP4I) and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2I) Added to Insulin Therapy in Type 2 Diabetes

Value in Health ◽

10.1016/j.jval.2015.09.2050 ◽

2015 ◽

Vol 18 (7) ◽

pp. A599 ◽

Author(s):

J Yoon ◽

SH Min ◽

S Hahn ◽

YM Cho

Keyword(s):

Type 2 Diabetes ◽

Insulin Therapy ◽

Indirect Comparison ◽

Dipeptidyl Peptidase ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors

Download Full-text

Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization

The American Journal of Cardiology ◽

10.1016/j.amjcard.2021.11.013 ◽

2021 ◽

Author(s):

Beini Lyu ◽

Morgan E. Grams ◽

Alex Chang ◽

Lesley A. Inker ◽

Josef Coresh ◽

...

Keyword(s):

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Receptor Agonists ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Decision letter for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v1/decision1 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Review for "Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study"

10.1111/dom.14189/v1/review4 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Observational Study ◽

Dipeptidyl Peptidase ◽

Renal Diseases ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Diabetes Patients

Download Full-text

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Mayo Clinic Proceedings ◽

10.4065/mcp.2010.0469 ◽

2010 ◽

Vol 85 (12) ◽

pp. S27-S37 ◽

Author(s):

Jaime A. Davidson

Keyword(s):

Clinical Practice ◽

Dipeptidyl Peptidase ◽

Dipeptidyl Peptidase 4 ◽

Receptor Agonists ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporter 2 inhibitor empagliflozin

Annals of Saudi Medicine ◽

10.5144/0256-4947.2018.420 ◽

2018 ◽

Vol 38 (6) ◽

pp. 420-426 ◽

Author(s):

Chung-Huei Huang ◽

Yu-Yao Huang ◽

Brend Ray-Sea Hsu

Keyword(s):

Body Weight ◽

Dipeptidyl Peptidase ◽

Diabetic Patients ◽

Weight Changes ◽

Body Weight Changes ◽

Dipeptidyl Peptidase 4 ◽

Sodium Glucose Cotransporter ◽

Dipeptidyl Peptidase 4 Inhibitors

Download Full-text